Erosive Disease in Early Rheumatoid Arthritis Clinical Trial
Official title:
Multicenter, Prospective, Open-label, Cohort Study With Collection of Blood Samples and Ultrasound / MRI and X-ray Examination
Multicenter, prospective, open-label, cohort study. Primary objective: Determination of the
predictive value of US alone and in combination with cartilage biodegradation markers on
radiographic progression (change in Ratingen score)
Secondary objectives:
- Correlation of ultrasound synovitis score and clinical disease activity score
- Determination of the sensitivity of ultrasound erosion detection compared to MRI
- Assessment of the value of including tenosynovitis assessment for predicting
radiographic progression
- Assessment of the predictive value of ultrasound synovitis score at baseline for the
need to install biologic DMARDs
Status | Not yet recruiting |
Enrollment | 24 |
Est. completion date | October 2019 |
Est. primary completion date | April 2019 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients fulfilling all of the following inclusion criteria may be enrolled in the study: - male and female subjects, Age above 18 yrs - recent onset RA fulfilling the American College of Rheumatology (ACR) criteria (revised 2010) - Symptoms for at least 6 weeks - no previous DMARD treatment - no intraarticular steroid injections in the last 4 weeks before inclusion - no treatment with oral steroids exceeding the equivalent of 10mg prednisone per day in the last 2 weeks before inclusion - signed Informed Consent after being informed Exclusion Criteria: - History of inflammatory joint disease other than RA - History of active Tbc, histoplasmosis or listeriosis - History of lymphoma or other malignancies within 5 years - Contraindication for the use of DMARD's or biologics - Comorbidities: severe myocardial dysfunction, recent stroke (within 3 months), uncontrolled diabetes and other disease which in the opinion of the investigator, would put the subject at risk by participation in the trial - History of demyelinating disorders - persistent or recurrent infections - Pregnancy or breast feeding - no informed consent |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determination of the predictive value of US alone and in combination with cartilage biodegradation markers on radiographic progression (change in Ratingen score) | 12 months | No | |
Secondary | Correlation of ultrasound synovitis score and clinical disease activity score | 12 months | No | |
Secondary | Determination of the sensitivity of ultrasound erosion detection compared to MRI | 12 months | No | |
Secondary | Assessment of the value of including tenosynovitis assessment for predicting radiographic progression | 12 months | No | |
Secondary | Assessment of the predictive value of ultrasound synovitis score at baseline for the need to install biologic DMARDs | 12 months | No |